// App-Quantinova.ai

6018 : A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 PembroRad trial.

Researchers

Presenter

  • Xu Shan Sun

Principal Investigators

  • Yungan Tao

  • Laurent Martin

  • Marc Alfonsi

  • Jean Briac Prevost

  • Michel Rives

  • Cedrik Lafond

  • Jean-Marc Tourani

  • Julian Biau

  • Lionnel Geoffrois

  • Alexandre Coutte

  • Xavier Liem

  • Elodie Vauleon

  • Franck Drouet

  • Jean-Francois Ramee

  • Gabriel Waksi

  • Laura Sinigaglia

  • Anne Auperin

  • Jean Bourhis

Medical Centers

  • CHRU Jean Minjoz, Besancon Cedex, France

  • CH de Bretagne Sud, Lorient, France

  • Institut Gustave-Roussy, Villejuif, France

  • Radiotherapie, Centre G Le Conquerant, Le Havre, France

  • Institut Sainte Catherine, Avignon, France

  • Department of Medical Oncology, Centre Pierre Curie, Beuvry, France

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Clinique Victor Hugo, Le Mans, France

  • Chu de Poitiers, Poitiers Cedex, France

  • Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France

  • Department of Medical Oncology, Institut de Cancerologie de Lorraine, Vanduvre-Les-Nancy, France

  • Department of Radiotherapie, CHU Amiens, Amiens, France

  • Centre Oscar Lambret, Lille, France

  • Eugene Marquis Cancer Institute, Rennes, France

  • Centre Hospitalier Departemental Vendee, La Roche-Sur-Yon, France

  • GORTEC, Tours, France

  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Locations

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Serpin B3

Drug/Treatment

  • Pembrolizumab

  • Erbitux

  • Cisplatin

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02707588

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved